ADMA Biologics, Inc. announced the successful initial use of its Artificial Intelligence (?AI?) program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. Recently, ADMA successfully produced its first batch of ASCENIV?

utilizing this innovative ADMAlytics software to prospectively automate and realize efficiency improvements to plasma pooling during commercial manufacturing. ADMA expects broad implementation of the new ADMAlytics capabilities has the potential to provide for rapid realization of efficiencies across the Company?s supply chain and production operations.